Mobile

Open-label, single-arm, multicenter phase II study of matuzumab in combination with irinotecan background chemotherapy in subjects with epidermal growth factor receptor (EGFR)-expressing metastatic co...

Update Il y a 4 ans
Reference: EUCTR2005-001362-14

Open-label, single-arm, multicenter phase II study of matuzumab in combination with irinotecan background chemotherapy in subjects with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer that developed progressive disease while on therapy or within 4 weeks after termination of an irinotecan based regimen

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To determine the response rate of matuzumab in combination with irinotecan background chemotherapy for EGFR-expressing metastatic colorectal cancer which developed PD while on therapy or within 4 weeks after termination of therapy with an irinotecan-based regimen.

Inclusion criteria

  • Epidermal Growth Factor Receptor (EGFR) expressing, metastatic colorectal cancer

Links